Table 3. Adjusted Association Between Baseline Clinicopathologic and Laboratory Characteristics and Survival Outcomes.
| Characteristic | Progression or death, adjusted HR (95% CI) | P value | Death, adjusted HR (95% CI) | P value |
|---|---|---|---|---|
| ECOG PS, ≥2 vs 0-1 | 2.02 (1.09-3.74) | .03 | 2.87 (1.40-5.89) | .004 |
| Absolute neutrophil count | 1.08 (1.01-1.16) | .02 | 1.12 (1.04-1.22) | .004 |
| Metastatic sites, No. | 1.18 (0.95-1.48) | .14 | 1.15 (0.88-1.49) | .29 |
| PD-L1 TPS, % | 0.99 (0.99-1.01) | .70 | 1.00 (0.99-1.01) | .99 |
| Simplified comorbidity score | 1.03 (0.91-1.15) | .66 | 0.99 (0.88-1.11) | .87 |
| Ever smoker, no vs yes | 4.71 (1.15-19.29) | .03 | NA | NA |
| Age, y | NA | NA | 1.02 (0.99-1.01) | .99 |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NA, not applicable; PD-L1, programmed cell death ligand 1; TPS, tumor proportion score.